Cat. No. ARG0076
CAV1 Knockout A-549 is a human CRISPR/Cas9-edited alveolar epithelial adenocarcinoma cell line with disruption of the caveolin-1 gene. In the lung-derived A-549 background, this model supports analysis of caveolae biology, membrane trafficking, and signaling pathways regulated by CAV1, including EGFR, SRC-PTK2/FAK, PI3K-AKT, MAPK-ERK, mechanotransduction, and cholesterol homeostasis. Loss of CAV1 provides a useful system for studying epithelial adhesion, migration, endocytosis, and treatment response in lung cancer-relevant contexts using western blotting, phospho-signaling assays, microscopy, RNA-seq, cholesterol transport assays, and migration or invasion assays.
| Host Cell | A-549 |
| Morphology | Epithelial-like |
| Age | 58 years |
| Sex of Donor | Male |
| Gene Name | CAV1 |
| Gene Identifier | NCBI Gene ID 857 |
| Temperature | 37°C |
| Atmosphere | 5% CO₂ |
| Sterility testing | Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination. |
| Mycoplasma testing | Negative for mycoplasma through PCR analysis |
| Pathogens | Cells tested negative for HIV-1, HBV, and HCV. |
Intended Use: This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer: Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use.
This product is provided "AS IS". For Research Use Only. Not for human or animal therapeutic use.
The CAV1 Knockout A-549 Cell Line is a human CRISPR/Cas9-engineered cell model in which the CAV1 gene has been disrupted to eliminate functional caveolin-1 expression. This stable edited line is generated in A-549 cells, a human alveolar basal epithelial adenocarcinoma background, and provides an in vitro system for investigating caveolae-associated membrane organization, receptor signaling, and epithelial response programs in a lung-derived context.
A-549 cells are widely used as a pulmonary epithelial model because they retain alveolar type II-like features and support studies of epithelial barrier biology, lung cancer signaling, membrane trafficking, and pharmacologic response. As a human lung adenocarcinoma cell line, A-549 is relevant to research on tumor progression, epithelial plasticity, growth-factor signaling, and host response pathways. Its established use in imaging, biochemical signaling assays, and functional perturbation studies makes it a practical host background for defining how specific gene loss alters pulmonary epithelial behavior.
CAV1 encodes caveolin-1, a principal structural component of caveolae that forms membrane-associated complexes with factors including CAVIN1/PTRF, EHD2, EGFR, SRC, PTK2/FAK, ITGB1, NOS3, and filamin A. Caveolin-1 organizes lipid raft and caveolar microdomains and modulates signaling downstream of integrin engagement, EGF stimulation, TGF-beta1, mechanical stress, hypoxia, and altered cholesterol availability. Through these interactions, CAV1 regulates caveolae-mediated endocytosis, cholesterol trafficking, and mechanotransduction, while influencing SRC phosphorylation state, FAK/PTK2 signaling, AKT1 activation, MAPK1/MAPK3-driven ERK1/2 signaling, RHOA activity, CDH1-associated adhesion dynamics, and migratory behavior. Because these signaling axes are strongly linked to lung cancer, fibrosis-associated remodeling, and vascular or metabolic dysfunction, CAV1 loss is a useful perturbation for pathway-level studies.
In the A-549 background, knockout of CAV1 enables direct analysis of how caveolar disruption reprograms epithelial membrane architecture and signaling output in a lung cancer-relevant system. This model is particularly informative for examining dependencies between caveolae integrity and EGFR, PI3K-AKT, MAPK-ERK, integrin-SRC-FAK, or TGF-beta pathway activity, as well as the effects of altered cholesterol distribution on adhesion, motility, and growth control.
Researchers can apply this cell line in western blotting and phospho-signaling studies to assess SRC, FAK, AKT1, or ERK1/2 pathway responses; in RT-qPCR or RNA-seq to profile gene-expression changes following growth-factor, hypoxic, or mechanical perturbation; and in immunofluorescence or confocal microscopy to examine caveolae markers, membrane organization, and cytoskeletal remodeling. The model is also suited for co-immunoprecipitation of caveolar signaling complexes, cholesterol uptake or efflux assays, endocytosis measurements, migration and invasion assays, proliferation and apoptosis studies, and drug sensitivity testing in lung cancer and membrane-trafficking research workflows. Researchers may contact Ascent Research for additional technical information, product details, or related gene-edited cell models.
